Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Kevin L Peterson"'
Autor:
Andrea J French, Sekar Natesampillai, Ashton Krogman, Cristina Correia, Kevin L Peterson, Alecia Alto, Aswath P Chandrasekar, Anisha Misra, Ying Li, Scott H Kaufmann, Andrew D Badley, Nathan W Cummins
Publikováno v:
PLoS Pathogens, Vol 16, Iss 10, p e1008906 (2020)
Eradication of HIV-1 by the "kick and kill" strategy requires reactivation of latent virus to cause death of infected cells by either HIV-induced or immune-mediated apoptosis. To date this strategy has been unsuccessful, possibly due to insufficient
Externí odkaz:
https://doaj.org/article/43ec5f6e91a24ab2bbc1bd2c4e5d59c0
Autor:
Annapoorna Venkatachalam, Cristina Correia, Kevin L. Peterson, Xianon Hou, Paula A. Schneider, Annabella R. Strathman, Karen S. Flatten, Chance C. Sine, Emily A. Balczewski, Cordelia D. McGehee, Melissa C. Larson, Laura N. Duffield, X. Wei Meng, Nicole D. Vincelette, Husheng Ding, Ann L. Oberg, Fergus J. Couch, Elizabeth M. Swisher, Hu Li, S. John Weroha, Scott H. Kaufmann
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-16 (2024)
Abstract Recent studies indicate that replication checkpoint modulators (RCMs) such as inhibitors of CHK1, ATR, and WEE1 have promising monotherapy activity in solid tumors, including platinum-resistant high grade serous ovarian cancer (HGSOC). Howev
Externí odkaz:
https://doaj.org/article/10416db1db3e4dd388e15b58bcaf44a8
Autor:
Swaathi Jayaraman, Xinyan Wu, Krishna R. Kalari, Xiaojia Tang, Mary J. Kuffel, Elizabeth S. Bruinsma, Shahrzad Jalali, Kevin L. Peterson, Cristina Correia, Rachel A. Kudgus, Scott H. Kaufmann, Santosh Renuse, James N. Ingle, Joel M. Reid, Matthew M. Ames, Alan P. Fields, Matthew J. Schellenberg, John R. Hawse, Akhilesh Pandey, Matthew P. Goetz
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-16 (2023)
Abstract Endoxifen, a secondary tamoxifen metabolite, is a potent antiestrogen exhibiting estrogen receptor alpha (ERα) binding at nanomolar concentrations. Phase I/II clinical trials identified clinical activity of Z-endoxifen (ENDX), in endocrine-
Externí odkaz:
https://doaj.org/article/809fda6ff0ea4cad83dc611d55814884
Autor:
Aref Al‐Kali, Ibrahim Aldoss, Pamela J. Atherton, Carrie A. Strand, Bijal Shah, Jonathan Webster, Bhavana Bhatnagar, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Sarah A. Buhrow, Jianping Kong, Joel M. Reid, Alex A. Adjei, Scott H. Kaufmann
Publikováno v:
Cancer Medicine, Vol 12, Iss 23, Pp 21229-21239 (2023)
Abstract Background Despite recent approval of several new agents, relapsed acute lymphoblastic leukemia (ALL) remains challenging to treat. Sapanisertib (MLN0128/TAK‐228) is an oral TORC1/2 inhibitor that exhibited preclinical activity against ALL
Externí odkaz:
https://doaj.org/article/55ca42b54be149f0b8acb389ece68dc9
Autor:
Guru Subramanian Guru Murthy, Antoine N. Saliba, Aniko Szabo, Alexandra Harrington, Sameem Abedin, Karen Carlson, Laura Michaelis, Lyndsey Runaas, Arielle Baim, Alex Hinman, Sonia Maldonado-Schmidt, Annapoorna Venkatachalam, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Mark Litzow, Scott H. Kaufmann, Ehab Atallah
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Azacitidine/venetoclax is an active regimen in patients with newly diagnosed AML. However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of MCL-1 is suggested to be a potential resistance mechan
Externí odkaz:
https://doaj.org/article/950acd891d7543f3b377e2a769eccff7
Autor:
Antoine N. Saliba, Scott H. Kaufmann, Eytan M. Stein, Prapti A. Patel, Maria R. Baer, Wendy Stock, Michael Deininger, William Blum, Gary J. Schiller, Rebecca L. Olin, Mark R. Litzow, Tara L. Lin, Brian J. Ball, Michael M. Boyiadzis, Elie Traer, Olatoyosi Odenike, Martha L. Arellano, Alison Walker, Vu H. Duong, Tibor Kovacsovics, Robert H. Collins, Abigail B. Shoben, Nyla A. Heerema, Matthew C. Foster, Kevin L. Peterson, Paula A. Schneider, Molly Martycz, Theophilus J. Gana, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Alice S. Mims, Uma Borate, Amy Burd, Brian J. Druker, Ross L. Levine, John C. Byrd, James M. Foran
Publikováno v:
Blood Advances. 7:2360-2363
Autor:
Haiming Dai, Kevin L. Peterson, Karen S. Flatten, X. Wei Meng, Annapoorna Venkatachalam, Cristina Correia, Marina Ramirez-Alvarado, Yuan-Ping Pang, Scott H. Kaufmann
Publikováno v:
Cell Death & Differentiation. 30:794-808
Autor:
Scott H. Kaufmann, Larry M. Karnitz, Hu Li, Keith W. Pratz, Judith E. Karp, B. Douglas Smith, Gabriel Ghiaur, Jonathan A. Webster, Mrinal Patnaik, Sun-Hee Lee, Cristina Correia, Kevin L. Peterson, Karen S. Flatten, Paula A. Schneider, X. Wei Meng, Annapoorna Venkatachalam, Brian D. Koh, Mira A. Kohorst, Cordelia D. McGehee, Nicole D. Vincelette, Husheng Ding
Supplementary methods, three supplementary tables and 16 supplementary figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dc8d64060cf335d74052c55f5b1496f
https://doi.org/10.1158/0008-5472.22427530.v1
https://doi.org/10.1158/0008-5472.22427530.v1
Autor:
Scott H. Kaufmann, Larry M. Karnitz, Judith E. Karp, B. Douglas Smith, Allan D. Hess, David Parry, Kevin L. Peterson, Karen S. Flatten, Brian D. Koh, Erin L. Schenk
PDF file, 105K, This file contains Supplemental Table 1 (Description of Patients Providing Samples for Assessment of Chk1 phosphorylation ), Supplemental Table 2 (Quantitative Effects of Cytarabine, SCH 900776 and the Combination on Samples from Pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28e74d3cfcac72f17f8e70d96ea6cd83
https://doi.org/10.1158/1078-0432.22456335
https://doi.org/10.1158/1078-0432.22456335
Autor:
Scott H. Kaufmann, Larry M. Karnitz, Hu Li, Keith W. Pratz, Judith E. Karp, B. Douglas Smith, Gabriel Ghiaur, Jonathan A. Webster, Mrinal Patnaik, Sun-Hee Lee, Cristina Correia, Kevin L. Peterson, Karen S. Flatten, Paula A. Schneider, X. Wei Meng, Annapoorna Venkatachalam, Brian D. Koh, Mira A. Kohorst, Cordelia D. McGehee, Nicole D. Vincelette, Husheng Ding
Although inhibitors of the kinases CHK1, ATR, and WEE1 are undergoing clinical testing, it remains unclear how these three classes of agents kill susceptible cells and whether they utilize the same cytotoxic mechanism. Here we observed that CHK1 inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e00427ec269deafe01c0b75797943fd
https://doi.org/10.1158/0008-5472.c.6512716.v1
https://doi.org/10.1158/0008-5472.c.6512716.v1